Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Seogsong JeongSeulggie ChoiSang Min ParkJinseok KimByeongzu GhangEun Young LeePublished in: Arthritis research & therapy (2022)
HZ risk is significantly increased in RA patients with a history of HZ after the initiation of bDMARDs or tsDMARD. The risk of incident and recurrent HZ was higher after tofacitinib treatment in patients with RA than that after treatment with bDMARDs. Individualized characteristics and history of HZ should be considered when selecting bDMARDs or tsDMARD for RA patients considering HZ risks.
Keyphrases
- rheumatoid arthritis
- disease activity
- rheumatoid arthritis patients
- end stage renal disease
- cardiovascular disease
- ankylosing spondylitis
- ejection fraction
- systemic lupus erythematosus
- newly diagnosed
- chronic kidney disease
- prognostic factors
- interstitial lung disease
- risk assessment
- systemic sclerosis
- ulcerative colitis
- smoking cessation
- replacement therapy